Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01343966 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 448
- Enrollment target
NCT01343966: Completed Phase 2 study, sponsored by Genentech.
NCT01343966 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 448 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (237% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01343966, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 448 participants
- Enrollment target
Study Summary
This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the safety and efficacy of MABT5102A in patients with mild to moderate Alzheimer's Disease.
Interventions
- DRUG placebo
- DRUG MABT5102A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2011-04-30 |
| Est. Completion | 2014-02-28 |
| Phase | Phase 2 |
What the finished NCT01343966 record still lists
NCT01343966 is an interventional study that assigns participants to a tested intervention. The registered 448 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (237% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01343966 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01343966 about?
NCT01343966 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)". This is a Phase II, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the safety and efficacy of MABT5102A in patients with mild to moderate Alzheimer's Disease.
What is the current status of trial NCT01343966?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 448 participants. The study started on 2011-04-30. Estimated completion is 2014-02-28.
What interventions are being tested in trial NCT01343966?
The interventions under investigation include: placebo (DRUG), MABT5102A (DRUG).
Who is sponsoring clinical trial NCT01343966?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01343966's enrollment target sits among peer trials
448 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06702449 · 448 participants · Phase 1
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
- NCT07125053 · 448 participants · NA
COPD Resources, Education, and Activity Designed for You Study
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI